Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

RationalePleural effusion commonly complicates community-acquired pneumonia (CAP) and is associated with intense pleural inflammation. Whether anti-inflammatory treatment with corticosteroids improves outcomes is unknown.ObjectivesTo assess the effects of corticosteroids in an adult population with pneumonia-related pleural effusion.MethodsSTOPPE was a pilot, multicenter, double-blinded, placebo-controlled randomized trial involving six Australian centers. CAP patients with pleural effusion were randomized (2:1) to intravenous dexamethasone (4mg twice daily for 48 hours) or placebo and followed for 30 days. Given the diverse effects of corticosteroids, a comprehensive range of clinical, serological, and imaging outcomes were assessed in this pilot trial (ACTRN12618000947202).Results80 patients were randomized (1 withdrawn before treatment) and received dexamethasone (n=51) or placebo (n=28). This pilot trial found no preliminary evidence of benefits of dexamethasone in improving time to sustained (>12 hours) normalization of vital signs (temperature, oxygen saturations, blood pressure, heart, and respiratory rates): median 41·0 [95%CI 32·3-54·5] vs 27·8 [15·4-49·5] hours in the placebo arm, HR 0·729 [95%CI 0·453-1·173], p=0·193. Similarly, no differences in C-reactive protein or leukocyte counts were observed except for a higher leukocyte count in the dexamethasone group at Day 3. Pleural drainage procedures were performed in 49·0% of dexamethasone-treated and 42·9% of placebo-treated patients, p=0·60. Radiographic pleural opacification decreased over time with no consistent inter-group differences. Mean duration of antibiotic therapy (22·4 [SD=15·4] vs 20·4 [SD=13·8] days) and median hospitalization (6·0 [IQR=5·0-10·0] vs 5·5 [IQR=5·0-8·0] days) were similar between the dexamethasone and placebo groups. Serious adverse events occurred in 25·5% of dexamethasone-treated and 21·4% of placebo-treated patients. Transient hyperglycemia more commonly affected the dexamethasone group (15·6% vs 7·1%).ConclusionsSystemic corticosteroids showed no preliminary benefits in adults with parapneumonic effusions. Clinical trial registration available at https://anzctr.org.au/, ID: ACTRN12618000947202.

Original publication

DOI

10.1164/rccm.202107-1600oc

Type

Journal article

Journal

American journal of respiratory and critical care medicine

Publication Date

26/01/2022

Addresses

Sir Charles Gairdner Hospital, 5728, Respiratory Medicine, Nedlands, Australia.